Topic: Psychotic Disorders

« Back

Print this page

	Personalized Program The Personalized Program enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log in to use the Personalized Program.	» Login » Identification » Help

	Sunday, 28. June 2009	next day »

No.	S-03 - Symposium
Time:	08.00-09.30
Room:	Room 352AB
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	Serotonin receptors in endophenotypic variations and treatment of schizophrenia: Genetic, neurocognitive, and pharmacological perspectives
	Tomiki Sumiyoshi, Japan	Chair
	Vera Bubenikova-Valesova, Czech Republic	Co-Chair

001	Multimodal imaging genetics on serotonin receptor polymorphisms in schizophrenia
	Jiri Horacek, Czech Republic	Speaker
002	Improving cognitive function in animal models of schizophrenia: Focus on serotonin receptors
	Vera Bubenikova-Valesova, Czech Republic	Speaker
003	Learning and memory in 5-HT1A-receptor mutant mice
	Bettina Bert, Germany	Speaker
004	Serotonin-1A receptors and cognitive enhancement in schizophrenia: Evidence from translational research
	Tomiki Sumiyoshi, Japan	Speaker

No.	FC-03 - Free Communications
Time:	08.00-09.30
Room:	Room 242B
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders I
	Sven Cichon, Germany	Chair
	Geraldo F. Busatto, Brazil	Co-Chair

001	Bringing 'dealing with stigma' into clinics: Why should 'stigma' not be a part of routine clinical assessment in schizophrenia: Need for objective assessment and quantification
	Amresh Shrivastava, Canada	Speaker
002	Differences among bipolar disorder and schizophrenia: Less and less feasible - breaking a dogma (Kraepelin´s dichotomy)
	Enrique Galli, Peru	Speaker
003	Sensitivity to expressions of pain by schizophrenia patients - neurocognitive and symptoms correlates
	Mauricio Martins, Portugal	Speaker
004	The navel hypothesis of schizophrenia: The meaning of schizophrenia: Synishophrenia instead of schizophrenia?
	Marko Kraljevic, Croatia	Speaker
005	Longitudinal assessment of adolescents with 22q11.2 Deletion Syndrome: Cognitive and cerebral correlates to enhanced risk for psychosis
	Martin Debbane, Switzerland	Speaker
006	Quantitative motor activity in psychotic disorders
	Sebastian Walther, Switzerland	Speaker

No.	S-10 - Symposium
Time:	11.00-12.30
Room:	Room 252B
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	Disturbed synaptic plasticity in schizophrenia? The evidence, visualisation and modulation.
	William G. Honer, Canada	Chair
	Peter Falkai, Germany	Co-Chair

001	How good is the evidence from post-mortem studies?
	William G. Honer, Canada	Speaker
002	Using in-vivo imaging: Can we see synaptic processes directly?
	Gunther Helms, Germany	Speaker
003	NRG-1, synaptic processes and schizophrenia
	Stephen Lawrie, United Kingdom	Speaker
004	Enhancing synaptic processes via exercise? Is there evidence for schizophrenia?
	Frank-Gerald Pajonk, Germany	Speaker

No.	FC-05 - Free Communications
Time:	12.30-14.00
Room:	Room 242A
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders II
	Bernhard Bogerts, Germany	Chair
	Jiri Horacek, Czech Republic	Co-Chair

001	The interhemispheric pathway in hearing: Relationship to auditory hallucinations in schizophrenia
	Christoph Mulert, USA	Speaker
002	Action of Psychotomimetic Ketamine on ongoing y oscillations: EEG, network and cellular features
	Didier Pinault, France	Speaker
003	Analysis of Single Nucleotide Polymorphisms (SNPs) of Serotonin receptors for schizophrenia in Malaysia population
	Han Chern Loh, Malaysia	Speaker
004	Prenatal exposure to infection: A primary mechanism for abnormal dopaminergic development relevant to schizophrenia
	Joram Feldon, Switzerland	Speaker
005	Attentional modulation of external speech perception in patients with hallucinations and delusions
	Lana Marija Ilankovic, Germany	Speaker
006	Prevalence of human parvovirus B19 infection in schizophrenia
	Mouna Ayachi, Tunisia	Speaker

No.	P-06 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders I
	Rainer Rupprecht, Germany	Chair

001	Compliance therapeutic adhesion over 8 year of follow-up in first psychotic episodes
	Sara Barbeito, Spain	Presenter
002	Impact of methamphetamine use in first episode psychosis
	Bonginkosi Chiliza, South Africa	Presenter
003	Greek translation and reliability of the Psychotic Symptom Rating Scales (PSYRATS)
	Costas Kollias, Greece	Presenter
004	Heart rate variability and Antrieb (drive, impulse) in catatonic schizophrenias - affection of the autonomic nervous system as a possible link between neurophysiological and psychopathological variables
	Felix Hohl-Radke, Germany	Presenter
005	Two days treatment of auditory hallucinations by high frequency rTMS guided by cerebral imaging: A 6 months follow - up study
	Aurelie Montagne-Larmurier, France	Presenter
006	Glutathione redox system and lipid peroxidation in patients with schizophrenia
	Anastasia Ivanova, Russia	Presenter
007	'Theory of mind’ in ultra high risk and first episode psychosis cohorts: Preliminary findings on degree of impairment
	Cali Bartholomeusz, Australia	Presenter
008	Risperidon, right choice of treatment for schizophrenia? Experience obtained through practice
	Aleksandar Macic, Serbia and Montenegro	Presenter
009	Abnormalities in the spontaneous and steady-state EEG activity of schizophrenics
	Fabio Ferrarelli, USA	Presenter
010	Effects of Selegiline on negative symptoms in schizophrenia: A double-blind, placebo-controlled, study
	Ebrahim Abdollahian, Iran	Presenter
011	The schizophrenia silent shout: The apathy
	Daniel Dachesky, Argentina	Presenter
012	Deficits in the inhibition of Gamma Oscillations in the Dorsolateral Prefrontal Cortex of patients with schizophrenia compared with Bipolar Disorder and healthy controls
	Faranak Farzan, Canada	Presenter
013	Implication of cryoglobulins in term of schizophrenia-associated immune system alterations
	Aren Khoyetsyan, Armenia	Presenter
014	Recognition of positive and negative emotions in schizophrenic patients: A experimental paradigm with faces
	Francisco Pizarro, Chile	Presenter
015	Atypical side effects of Antipsychotics - risk factor for noncompliance in first episode of schizophrenia
	Gabriela Grigorescu, Romania	Presenter
016	Cognitive impairment profile in schizophrenia
	Gabriela Grigorescu, Romania	Presenter
017	Efficacy of aripiprazole vs quetiapine for the treatment of hostility in acute patients with schizophrenia
	Gabriela Grigorescu, Romania	Presenter
018	Parametric variation in working memory demand in patients with schizophrenia: A behavioral and neuroimaging pilot study
	Jared Van Snellenberg, USA	Presenter
019	Disturbance of metacognition of agency in patients with schizophrenia
	Jared Van Snellenberg, USA	Presenter

No.	P-07 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders II
	Pichet Udomratn, Thailand	Chair

001	Epileptic psychosis: A report of three cases
	Cristina Gonzalez Mingot, Spain	Presenter
002	Enhanced cortisol suppression in response to dexamethasone administration in first episode psychosis patients
	Christina Phassouliotis, Australia	Presenter
003	Inflammatory component in pathogenesis of schizophrenia and post-traumatic stress disorder
	Anna Boyajyan, Armenia	Presenter
004	Circadian melatonin rhythm in paranoid schizophrenic patients
	Estefania Diaz Mesa, Spain	Presenter
005	Do patients with auditory hallucinations have auditory processing deficits?
	Dougal Phillips, Australia	Presenter
006	Environmental Supports Improve Negative Symptoms in Schizophrenia
	Natalie Maples, USA	Presenter
007	Reduced early auditory evoked gamma band response in patients with schizophrenia
	Gregor Leicht, Germany	Presenter
008	Autoimmunity in bipolar and schizophrenic disorders
	Maria Isabel Ganhao Rodrigues, Portugal	Presenter
009	Single trial P3a/P3b deficits discriminate cognitive deficits in borderline personality disorder from schizophrenia
	Kerri Brown, Australia	Presenter
010	Electroconvulsive Therapy (ECT) in schizophrenia associated with violence: A case series
	Mrigendra Das, United Kingdom	Presenter
011	Latency classification of the frontal MMN responses to the pitch deviants in schizophrenic patients
	Josef Zislin, Israel	Presenter
012	Efficacy of haloperidol and quetiapine combination in refractory schizophrenia: A case report
	Michalis Saitis, Greece	Presenter
013	Gamma-interferon and interleukin-4 levels in the process of treatment of schizophrenic patients
	Olga Lobacheva, Russia	Presenter
014	Substance use disorder comorbidity in Latinos with schizophrenia
	Lorena Jimenez Castro, USA	Presenter
015	New-onset psychosis associated with HIV infection treated with HIV antiretroviral medications and inclusion of HIV medication in involuntary mental health treatment
	Melissa Corr, Australia	Presenter
016	The effect of cigarette smoking on prepulse inhibition and P50 suppression in Japanese patients with schizophrenia
	Kazumichi Hashimoto, Japan	Presenter
017	Influence of infections on schizophrenic patients
	Daniela Friebel, Germany	Presenter
018	Types of transaction in the family as they are expressed in space arrangements and the habits in the house with schizophrenic
	Nikolaos Marketos, Greece	Presenter
019	Antineuronal Antibodies in a schizophrenic patient and his family
	Konstantinos Kylintireas, Greece	Presenter

« previous day	Monday, 29. June 2009	next day »

No.	FC-07 - Free Communications
Time:	08.00-09.30
Room:	Room 351
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders III
	Shigenobu Kanba, Japan	Chair
	Norbert Müller, Germany	Co-Chair

001	Can the writing of patients with schizophrenia be identified by means of automated computer-aided analysis?
	Rael Strous, Israel	Speaker
002	The relation between the general intellect of schizophrenic patients and psychopathological deterioration
	Eka Chkonia, Georgia	Speaker
003	Cannabis use and cognitive functioning in schizophrenia
	Antony Henderson, Australia	Speaker
004	Effects of cannabis use on cognitive deficits in first-episode psychosis
	Murat Yucel, Australia	Speaker
005	Association between neurocognitive factors and homicide in schizophrenia: A systematic review
	Stephane Richard-Devantoy, France	Speaker
006	Parameters of quantitative EEG correlate with negative symptoms in neuroleptic-naive patients with first episode schizophrenia
	Ronan Zimmermann, Switzerland	Speaker

No.	S-36 - Symposium
Time:	11.00-12.30
Room:	Room 251
Topic:	Psychotic Disorders
Track:	3 Interface
Session title:	Psychophysiological endophenotypic makers in prodromal and first-episode schizophrenia patients
	Birte Glenthoj, Denmark	Chair
	Raquel Gur, USA	Co-Chair

001	Endophenotype candidacy of key psychophysiological disturbances in schizophrenia
	Raquel Gur, USA	Speaker
002	Deficits in prepulse Inhibition in the prodrome of schizophrenia
	Boris Quednow, Switzerland	Speaker
003	Effects of a six month antipsychotic treatment on sensory(motor) gating and its neural generators: A longitudinal study of antipsychotic-naive first-episode schizophrenic patients
	Bob Oranje, Denmark	Speaker
004	Vulnerability markers in the prodrome in early psychosis: Predicting outcome and understanding the mechanism
	Kristin Cadenhead, USA	Speaker

No.	FC-10 - Free Communications
Time:	12.30-14.00
Room:	Room 351
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders IV
	Werner Strik, Switzerland	Chair
	Nash Boutros, USA	Co-Chair

001	D2/3-Receptor availability in schizophrenia decreases with progression of psychosis: An [18F] Fallypride Study
	Ingo Vernaleken, Germany	Speaker
002	Increased EEG sources (LORETA) in the left hemisphere of sinistral male schizophrenics and in the right hemisphere of dextral male schizophrenics
	Pierre Flor-Henry, Canada	Speaker
003	Erythrocyte membrane fatty acids and transition to psychosis in ultra-high risk individuals: Basic research findings from a RCT
	G. Paul Amminger, Australia	Speaker
004	Impaired predictive component of smooth pursuit in schizophrenia
	Irene Nkam, France	Speaker
005	Neurocognitive impairments among first-epidode psychotic patients without drug consumption
	Irene Vanelli, Portugal	Speaker
006	State and trait aspects of auditory oddball event-related potentials in schizophrenia
	Irina Lebedeva, Russia	Speaker
007	The clinical correlate of neurological soft signs in an epidemiologically representative sample of first episode psychosis patients. Evidence from the Picos Veneto study
	Sarah Tosato, Italy	Speaker

No.	P-16 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders III
	Bernhard Bogerts, Germany	Chair

001	Adjunctive Aripiprazole: A good strategy for Clozapine induced metabolic syndrome
	Michel Soufia, Lebanon	Presenter
002	The effect of weight loss on obesity-related quality of life and body image in obese schizophrenic patients
	Bo-Hyun Yoon, Korea, Republic of	Presenter
003	Hypersensitivity to MK-801 - induced hyperlocomotion in a neurodevelopmental model for schizophrenia: Reversal by antipsychotics
	Gwenaëlle Le Pen, France	Presenter
004	Effects of olanzapine-treatment on cell mitotic activity in the hypothalamus and adipose tissue of mice
	Yamauchi Takahira, Japan	Presenter
005	A randomized controlled study of cognitive remediation in schizophrenia (RECOS: Cognitive Remediation in Schizophrenia vs CRT: Cognitive Remediation Therapy)
	Gabrielle Chesnoy, France	Presenter
006	Apathy and cognition in schizophrenia
	Georgios Konstantakopoulos, Greece	Presenter
007	Mentalizing and awareness of illness in schizophrenia
	Georgios Konstantakopoulos, Greece	Presenter
008	Effect of carbamazepine on behavioral troubles with schizophrene patient
	Grégoire Magloire Gansou, Benin	Presenter
009	Synaptosomal-associated protein (snap-25) polymorphisms and response to olanzapine in schizophrenia patients
	Hasan Herken, Turkey	Presenter
010	Changes in oxy - hemoglobin during emotionally loaded shiritori task in schizophrenic patients evaluation by NIRS
	Kiichiro Morita, Japan	Presenter
011	Characteristics of emotional charged P300 component in patients with schizophrenia: Comparison with healthy controls
	Keiichiro Mori, Japan	Presenter
012	Omega-3 fatty acids reduce serum triglyceride levels in individuals at ultra-high risk for psychosis
	Konstantinos Papageorgiou, Austria	Presenter
013	Inspection time, intelligence and cognition in schizophrenia
	Linley Denson, Australia	Presenter
014	Source monitoring seems to be more affected in paranoid than in non-paranoid schizophrenia
	Monica N. Toba, France	Presenter
015	Translational modeling of the asenapine plasma concentration dopamine D2 receptor occupancy relationship in rats and humans
	Mohammed Shahid, United Kingdom	Presenter
016	Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: Possible relevanceto neuroprotective interventions in Schizophrenia
	Tsung-Tsair Yang, Taiwan	Presenter
017	Niacin sensitvity different in people at risk to develop psychosis and in first-episode schizophrenia patients
	Stefan Smesny, Germany	Presenter
018	Niacin sensivity, membrane fatty acids and phospholipase A2 activity: Associations in people at rist to develop psychosis
	Stefan Smesny, Germany	Presenter
019	Frontal lobes MRI-peculiarities and auto antibodies to nerve growth factor (NGF) in families of patients with schizophrenia
	Natalia Efanova, Russia	Presenter

No.	P-17 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders IV
	Veronica Larach-Walters, Chile	Chair

001	Psychological and neuropsychological similarities and discrepancies of triplets suffering from atypical schizophrenia
	Dimitrios Dikeos, Greece	Presenter
002	Study of schizophrenia
	Andrey Starytsyn, Russia	Presenter
003	The impact of smoking on the schizophrenic relapses
	Gavril Cornutiu, Romania	Presenter
004	Hypofrontality and the frontal-striata-thalamic pathway during varied attentional tasks in schizophrenia
	Monte Buchsbaum, USA	Presenter
005	Olanzapine orally disintegrating tablets cause no moresedation than standard tablets in a small outpatient sample
	Emmanuil Patelaros, Greece	Presenter
006	Traumatic brain injury and secondary psychosis
	Rachel Batty, Australia	Presenter
007	Relation of 18F-fallypride binding potential and antipsychotic treatment response in patients with schizophrenia
	Monte Buchsbaum, USA	Presenter
008	The effect of ketamine on behavior and quantitative EEG - an animal model of psychosis
	Tomas Palenicek, Czech Republic	Presenter
009	Public mistrust of DNA biobank studies in Malaysia
	Han Chern Loh, Malaysia	Presenter
010	Where does evidence from new trials for schizophrenia fit with the existing evidence: A case of the Emperor’s new clothes?
	Mahesh Jayaram, United Kingdom	Presenter
011	HPA axis functioning in schizophrenic patients
	Mário Simões, Portugal	Presenter
012	Association between the leukemia inhibitory factor gene and schizophrenia and cognitive functions
	Yuko Okahisa, Japan	Presenter
013	Neurocognitive deficits in schizophrenia measured by the Cambridge Neuropsychological Test Automated Battery
	Nóra Domján, Hungary	Presenter
014	Auditory mismatch negativity deficits in long-term heavy cannabis users
	Patrik Roser, Germany	Presenter
015	The conscious mind and quantum mechanics
	Fernando Corona, Mexico	Presenter
016	Water poisoning with SCH patients in conjunction with psychotic perceptions
	Snjezana Ler, Bosnia and Herzegovina	Presenter
017	Neuropsychological functioning and plasma levels of homocysteine in early - onset schizophrenia forensic patients compared with adult - onset - schizophrenia forensic patients and normal controls
	Konstanze Dorothea Römer, Switzerland	Presenter
018	Preliminary study of ABO blood group distribution in schizophrenia
	Pek Yee Tang, Malaysia	Presenter
019	Role of carotenoid level in schizophrenia
	Han Chern Loh, Malaysia	Presenter

No.	S-37 - Symposium
Time:	16.00-17.30
Room:	Blue Amphitheatre
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	Psychoses at the interface between neurology and psychiatry
	Michael Trimble, United Kingdom	Chair
	Pierre Flor-Henry, Canada	Co-Chair

001	Epilepsy and psychosis - an epidemiological view
	Dale Hesdorffer, USA	Speaker
002	Psychosis, neurological soft signs and their meaning
	Paola Dazzan, United Kingdom	Speaker
003	Epilepsy and psychosis - anatomy and physiology
	Michael Trimble, United Kingdom	Speaker
004	On the question of the lateralization of epilepsy in the manic-depressive syndrome and depression
	Pierre Flor-Henry, Canada	Speaker

« previous day	Tuesday, 30. June 2009	next day »

No.	S-48 - Symposium
Time:	08.00-09.30
Room:	Room 251
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	New findings on the neurobiological basis of language abnormalities in schizophrenia
	Werner Strik, Switzerland	Chair
	Robert McCarley, USA	Co-Chair

001	Contribution of gene-brain interaction to language abnormalities in schizophrenia
	Tilo Kircher, Germany	Speaker
002	Disordered thought and impaired connectivity of language regions in schizophrenia
	Robert McCarley, USA	Speaker
003	Abnormalities of the language circuitry in schizophrenic thought disorders and hallucinations
	Werner Strik, Switzerland	Speaker
004	Language deficits in schizophrenia: Evidence from behavioral, functional and connectivity studies
	Ruben Gur, USA	Speaker

No.	FC-17 - Free Communications
Time:	08.00-09.30
Room:	Room 242B
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders V
	Rainald Mössner, Germany	Chair
	Michael Musalek, Austria	Chair

001	A functional MRI study of face perception in patients with schizophrenia
	Yasuhiro Kawasaki, Japan	Speaker
002	Arousal-cognition decoupling in Schizophrenia: An EEG-fMRI study
	Jack Foucher, France	Speaker
003	Global abnormalities in white and gray matter of chronic schizophrenia: A diffusion tensor imaging study
	Motoaki Nakamura, Japan	Speaker
004	Detection of 6p25 region in male schizophrenia via fluorescence in SITU hybridization (FISH) techniques
	Pappuswamy Manikantan, India	Speaker
005	Metabolic derangement in schizophrenia: Relation to antipsychotic treatment
	Marwa Soltan, Egypt	Speaker
006	Influence of antypsychotic treatment on cognitive functions in schizophrenia with comorbid addiction to substances
	Krzysztof Krysta, Poland	Speaker

No.	YS-03 - Young Scientists Award Session
Time:	09.45-10.30
Room:	Room 242A
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders I
	Michel Dierick, Belgium	Chair
	Gerhard Gründer, Germany	Co-Chair

001	Plasmatic Glutathione levels and their relationships with clinical and therapeutic features in schizophrenic patients
	Monia Raffa, Tunisia	Speaker
002	What can the N170 tell us about face processing in schizotypy?
	Rachel Batty, Australia	Speaker
003	Identification of novel Clozapine interactions with the Phosphatidyl Inositol 3-Kinase (PI3K)/Insulin signaling pathway in a Caenorhabditis elegans model system
	Rakesh Karmacharya, USA	Speaker

No.	S-50 - Symposium
Time:	11.00-12.30
Room:	Room 352AB
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	Microglia in psychiatric disorders
	Natalia Uranova, Russia	Chair
	Norbert Müller, Germany	Co-Chair

001	Microglia as an immune source: The possible role in schizophrenia and depression
	Norbert Müller, Germany	Speaker
002	Glial Cell Changes and Gene expression in the Brain and Blood in Schizophrenia
	Ian Everall, USA	Speaker
003	The distribution of microglia in post-mortem brains of patients with schizophrenia and depression
	Johann Steiner, Germany	Speaker
004	Ultrastructural abnormalities of microglial cells in post-mortem brains in schizophrenia
	Natalia Uranova, Russia	Speaker

No.	P-25 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders V
	Norio Ozaki, Japan	Chair

001	Reaction time to sound and light in schizophrenic patients and normal people
	Alireza Homayouni, Iran	Presenter
002	Reasons for adherence to antipsychotic treatment: The patient's perspective
	Antonio Ciudad, USA	Presenter
003	Plasma homocysteine, folate and B12 levels in Tunisian patients with schizophrenia
	Anwar Mechri, Tunisia	Presenter
004	Niacin skin flush response in schizophrenia linked to soluble interleukin 2 receptor serum levels
	Berko Milleit, Germany	Presenter
005	TH-1/TH - 2 cytokine imbalance more pronounced in neuroleptic - naïve first episode schizophrenia
	Berko Milleit, Germany	Presenter
006	Expressiveness and recognition of self-generated facial emotions are impaired in schizophrenia
	Caroline Demily, France	Presenter
007	Addition of aripiprazole improves antipsychotic-induced hyperprolactinemia and reverses amenorrhea: Two cases
	Paraskevi Kotorki, Greece	Presenter
008	Fugue and aphonia as first and foremost presentations of a case of psychosis
	Ioanna Fotara, Greece	Presenter
009	Self-other discrimination in schizophrenic patients
	Christine Heinisch, Germany	Presenter
010	Suicide attempts in schizophrenic patients
	Christos Istikoglou, Greece	Presenter
011	A cognitive investigation of delusions: Are positive schizotypal symptoms associated with cognitive dysfunction and biases?
	Clare Cameron, Australia	Presenter
012	Serum proBDNF / BDNF ratio in patients with schizophrenia
	Davide Carlino, Italy	Presenter
013	The efficacy of atypical and classical antipsychotic agents in the acute treatment of schizoaffective disorders
	Djendji Siladji Mladenovic, Serbia and Montenegro	Presenter
014	Neurobiological vulnerabitlity determinded by vascular factor in schizophrenia
	Dragos Marinescu, Romania	Presenter
015	Neuroprotecion and cardioprotection for the antipsychotics with long - term action (animal model study)
	Laurentiu Mogoanta, Romania	Presenter
016	Negative symptoms in schizophrenia
	Edith Serfaty, Argentina	Presenter
017	Assessment of risk factors in tardive dyskinesia
	Melek Vardar, Turkey	Presenter
018	Minor physical anomalies in schizophrenic and schizoaffective patients and non - psychiatric controls: Assessment of group - and sex - specific differences
	Gordana Rubesa, Croatia	Presenter
019	Toluene exposure during adolescence produces long-lasting schizophrenia - like behaviors in mice
	Hwei-Hsien Chen, Taiwan	Presenter
020	Effects of Risperdal Consta on psychosocial functioning in schizophrenia
	Izabela Filov, Macedonia, The former Yugoslav	Presenter

No.	TG-06 - WFSBP Treatment Guidelines
Time:	16.00-17.30
Room:	Room 242A
Topic:	Psychotic Disorders
Session title:	Schizophrenia
	Birte Glenthoj, Denmark	Chair

	Carlo Altamura, Italy	Presenter
	Peter Falkai, Germany	Presenter

No.	S-55 - Symposium
Time:	16.00-17.30
Room:	Salle Maillot
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	EEG and MEG response to mismatch stimuli as an index of schizophrenia neurobiology and genetics
	Robert McCarley, USA	Chair
	Kiyoto Kasai, Japan	Co-Chair

001	Mismatch negativity from the prodrome to chronicity: Relationships with functional status, generator sources and grey matter loss
	Pat Michie, Australia	Speaker
002	Deficits in primary auditory cortex circuits in subjects with schizophrenia: Matching up with mismatch negativity
	Robert Sweet, USA	Speaker
003	MEG mismatch abnormalities to speech sounds in schizophrenia: Heritability and relationship to genetics
	Tsuyoshi Araki, Japan	Speaker
004	Mismatch negativity is associated with genetic, clinical, cognitive, and functional abnormalities of schizophrenia patients
	Gregory Light, USA	Speaker

« previous day	Wednesday, 1. July 2009	next day »

No.	S-65 - Symposium
Time:	08.00-09.30
Room:	Room 251
Topic:	Psychotic Disorders
Track:	3 Interface
Session title:	Functional psychopathology: Linking neurobiology with psychopathology
	Wolfgang Gaebel, Germany	Chair
	Veronica Larach-Walters, Chile	Co-Chair

001	Philosophical foundations of the relation between neurobiology and psychopathology
	Michael Musalek, Austria	Speaker
002	An introduction to functional psychopathology
	Wolfgang Gaebel, Germany	Speaker
003	Modules of the brain: Linking brain function to psychopathology
	Jürgen Zielasek, Germany	Speaker
004	Treatment of social cognition impairments in schizophrenia regarding facial affect recognition
	Veronica Larach-Walters, Chile	Speaker

No.	FC-23 - Free Communications
Time:	08.00-09.30
Room:	Room 351
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VI
	Michel Dierick, Belgium	Chair
	Margareta Reis, Sweden	Co-Chair

001	Outcome in first-episode schizophrenia: 4-year follow-up
	Eva Ceskova, Czech Republic	Speaker
002	New diagnostic and treatment approaches to schizophrenia with obsessive-compulsive symptoms
	Ilya Reznik, Israel	Speaker
003	Visual scanning of natural scenes in schizophrenia: Effect of a task-driven exploration and scene semantic consistency
	Emmanuelle Boloix, France	Speaker
005	Heritability aspects of endocannabinoid functioning in schizophrenia
	Dagmar Köthe, Germany	Speaker

No.	W-10 - Workshop
Time:	11.00-12.30
Room:	Room 242B
Topic:	Psychotic Disorders
Session title:	New tools for cognitive remediation in schizophrenia
	Nicolas Franck, France	Chair

001	Symptom oriented cognitive remediation in RECOS
	Pascal Vianin, Switzerland	Speaker
002	Cognition rehabilitation in schizophrenia: Costs and effectiveness
	Caroline Cellard, United Kingdom	Speaker

No.	FC-27 - Free Communications
Time:	12.30-14.00
Room:	Room 242A
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VII
	René Kahn, Netherlands	Chair
	Wolfgang Gaebel, Germany	Co-Chair

001	Some oxidative stress markers in schizophrenic patients with and without history of suicidal behavior
	Doina Cozman, Romania	Speaker
002	Theta Burst stimulation in schizophrenia
	Jerome Brunelin, France	Speaker
003	Oscillatory brain dynamics reflected in the frontal auditory evoked potentials in healthy subjects and schizophrenic patients
	Josef Zislin, Israel	Speaker
004	Obsessive-compulsive symptom dimensions in schizophrenia patients with obsessive-compulsive disorder
	Michael Poyurovsky, Israel	Speaker
005	Fast face recognition in schizophrenia and spatial frequency processing
	Vincent Laprévote, France	Speaker
006	Coherent analysis and clinical correlates in patients with first episode of schizophrenia and schizoaffective disorder
	Yuliya Zaytseva, Russia	Speaker

No.	P-35 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VI
	Mohammed Shahid, United Kingdom	Chair

001	Corpus callosum abnormalities in schizophrenia: Potential association to symptom cerebral substrate and age course of illness
	Giuseppe Bersani, Italy	Presenter
002	Factors associated with weight change in a 16-week randomized double-blind, double-dummy trial of sublingual orally disintegrating olanzapine vs. oral olanzapine in patients who gained weight during olanzapine treatment: The PLATYPUS Study
	Jamie Karagianis, Canada	Presenter
003	Disturbed prepulse inhibition in patients with schizophrenia is consequential to selective attention deficits
	Kirsty Scholes, Australia	Presenter
004	Subjective experience with an antipsychotic treatment
	Ludvik Nabelek, Slovak Republic	Presenter
005	Prepulse inhibition as a biological marker of at risk mental state of schizophrenia
	Masatoshi Okumura, Japan	Presenter
006	Discriminant analysis in schizophrenia and healthy controls using preforntal activation during forntal lobe tasks: A near-infrared spectroscopy study
	Michiyo Azechi, Japan	Presenter
007	Mismatch negativity in schizophrenia and patients at risk
	Mitja Bodatsch, Germany	Presenter
008	Hepatitis B in schizophrenia: Prevalence and comparison with healthy controls
	Mouna Ayachi, Tunisia	Presenter
009	Cariprazine (RGH-188), a potential antipsychotic with Dopamine D3/D2 functional antagonist properties, attenuates manic-like behaviors in animal models
	Nika Adham, USA	Presenter
011	Rational for the use of neurofeedback as a rehabilitation tool to overcome neurocognitive impairments in schizophrenia
	Nuno Rocha, Portugal	Presenter
012	Neurocognitive predictors of proactive coping in schizophrenia
	Nuno Rocha, Portugal	Presenter
013	A new tool to evaluate anxiety in schizophrenia : Anxiety Scale in Schizophrenia (ASS)
	Pierre-Marie Llorca, France	Presenter
014	Spectral karyotyping of schizophrenia populations in Tamilnadu, South India
	Pappuswamy Manikantan, India	Presenter
015	Cognitive antismoking and psychiatric effects of Varenicline in patients with schizophrenia or schizoaffective disorder
	Robert C. Smith, USA	Presenter
016	Schizophrenics show an upregulation of DNA-methyltransferase 1 (DNMT1)in blood lymphocytes: Implications for the epigenitic methylation hypothesis of schizophrenia
	Robert C. Smith, USA	Presenter
017	Treatment of schizophrenia with long-acting injectable risperidone
	Sanja Stanojkovic, Serbia and Montenegro	Presenter
018	Glutamate and BDNF levels in psychosis
	Sonia Ruiz de Azua, Spain	Presenter
019	Association of Psychopathology and Deficits in Facial Affect Recognition in Bimodal Context in Greek patients with schizophrenia
	Vassiliki Psarra, Greece	Presenter
020	Recurrence pattern of the patients who had been diagnosed with brief psychotic disorder: 2 years of follow up by retrospective chart review
	Won-Myong Bahk, Korea, Republic of	Presenter

No.	W-11 - Workshop
Time:	16.00-17.30
Room:	Room 242B
Topic:	Psychotic Disorders
Session title:	Pharmacological management of schizophrenia in pregnancy and the puerperium
	Angelika Wieck, United Kingdom	Chair

001	Antipsychotic therapy in pregnancy
	Margareta Reis, Sweden	Speaker
002	Antipsychotic therapy in breast-feeding
	Salvatore Gentile, Italy	Speaker

« previous day	Thursday, 2. July 2009

No.	S-80 - Symposium
Time:	08.00-09.30
Room:	Room 241
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	The neural bases of hallucinations in schizophrenia: Recent advances in research
	Kevin Spencer, USA	Chair
	Daniel Mathalon, USA	Co-Chair

001	Hallucination symptoms and oscillatory brain dynamics in schizophrenia
	Kevin Spencer, USA	Speaker
002	Corollary discharge dysfunction in Schizophrenia
	Judith Ford, USA	Speaker
003	Relation beween functional and structural cerebral changes in auditory verbal hallucinations
	Thomas Dierks, Switzerland	Speaker
004	Probing the pathophysiology of auditory/verbal hallucinations by combining fMRI and rTMS
	Ralph Hoffman, USA	Speaker

No.	FC-33 - Free Communications
Time:	08.00-09.30
Room:	Room 242B
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VIII
	Carlo Altamura, Italy	Chair
	N N	Co-Chair

001	Enhanced synaptic plasticity at hippocampal output synapses in the MK-801 model of psychosis
	Julia Bartsch, Germany	Speaker
002	Temporal processing dysfunction in medicated and unmedicated patients with schizophrenia
	Chara Malapani, USA	Speaker
003	Schizophrenia, serotonin, gender and age of onset: An association study in a Spanish sample
	Javier Gilabert Juan, Spain	Speaker
004	Cortical gyrification in twins discordant for schizophrenia
	Raka Maitra, Germany	Speaker
005	Silenced and overexpressed genes: Incorporating epigenetic factors in the Etio-Pathology of schizophrenia
	Zeinab Elbaz, USA	Speaker
006	Modelling thalamo-cortical circuits and auditory processing in schizophrenia
	Ralf Mueller, Germany	Speaker

No.	YS-05 - Young Scientists Award Session
Time:	09.45-10.30
Room:	Room 242A
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders II
	Olivier Blin, France	Chair
	Peter Riederer, Germany	Co-Chair

001	Spatial reference in schizophrenia
	Steffen Landgraf, Germany	Speaker
002	Schizophrenia: GSK-3ß and PLA2 dysregulation
	Augusto Vieira, Brazil	Speaker
003	Delusions in bipolar disorder: Similarities and differences with schizophrenia
	Susan Rossell, Australia	Speaker

No.	D-09 - Debate
Time:	11.00-12.30
Room:	Room 351
Topic:	Psychotic Disorders
Session title:	Have we learnt anything of clinical relevance about schizophrenia over the last 50 years?
	Michael Trimble, United Kingdom	Chair

	Dan Rujescu, Germany	Proponent
	Florence Thibaut, France	Opponent

No.	S-82 - Symposium
Time:	11.00-12.30
Room:	Room 352AB
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	Auditory sensory gating in schizophrenia: Towards a better understanding of the genetical, neurophysiological, and neurochemical underpinnings
	Anke Brockhaus-Dumke, Germany	Chair
	Nash Boutros, USA	Co-Chair

001	Clinical correlates of N100 gating deficit in schizophrenia
	Nash Boutros, USA	Speaker
002	Role of the frontal cortex in both auditory and somatosensory habituation: An MEG study
	Susan Bowyer, USA	Speaker
003	The neurochemical basis of sensory gating in humans
	Maarten van den Buuse, Australia	Speaker
004	Time-frequency analysis of auditory sensory gating in first episode patients and subjects at risk
	Anke Brockhaus-Dumke, Germany	Speaker

No.	P-45 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VII
	Rainald Mössner, Germany	Chair

001	Post-injection delirium/ sedation syndrome observed with olanzapine long-acting injection
	Angela Hill Gulliver, USA	Presenter
002	Visual scanning in schizophrenia: Effects of instructions on visual categorisation
	Céline Delerue, France	Presenter
003	Quantifying cortical thinning in first episode schizophrenia
	Christoph Schultz, Germany	Presenter
004	Effect of agonists of metabotropic glutamate receptors on schizophrenia like behavior in rats
	Karel Vales, Czech Republic	Presenter
005	Differential white matter alterations in schizophrenia: A study with DTI and tract-based spatial statistics
	Christoph Schultz, Germany	Presenter
007	Familial and sporadic schizophrenia: A comparison of somatic diseases and abuse in patients and their relatives
	Kristina Melkersson, Sweden	Presenter
008	One year outcome of first psychotic episode: Tunisian inpatients population
	Anwar Mechri, Tunisia	Presenter
009	Impact of Schizophrenia Candidate Genes on Antisaccade Task performance in a population of young men
	Nikolaos Smyrnis, Greece	Presenter
010	Larger time variability for basic decision processes in schizophrenia
	Nikolaos Smyrnis, Greece	Presenter
011	Long-term treatment with Asenapine versus Olanzapine in subjects with persistent negative symptoms of Schizophrenia
	Pilar Cazorla, USA	Presenter
012	Dose selection of asenapine: Application of mathematical models based on D2 receptor occupancy
	Rik Degreef, Netherlands	Presenter
013	Mentally Ill, Violence and Stigma
	Snezana Vladejic, Serbia and Montenegro	Presenter
014	Implicit planning of simple motor sequences in schizophrenia as measured by the Line-Sequencing Task
	Sofie Houthoofd, Belgium	Presenter
015	Psychobiology and prognosis of atypical psychosis
	Stefano Spanarello, Italy	Presenter
017	Subnanosecond fluorescence spectroscopy in the study of albumin binding sites in first - episode drug-naive patients with paranoid schizophrenia
	Yuriy Gryzunov, Russia	Presenter
018	Probabilistic classification and gambling in medicated schizophrenic patients: Comparison of olanzapine, risperidone, clozapine and typical antipsychotics
	Richard J. Beninger, Canada	Presenter

No.	P-46 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VIII
	Norbert Müller, Germany	Chair

001	Serum nitric oxide levels and schizophrenia: A pilot study
	Amra Memic, Bosnia and Herzegovina	Presenter
002	Oxidative stress - linked changes in patients with schizophrenia and metabolic syndrome
	Bogdan Nemes, Romania	Presenter
003	Schizophrenia deficits of interference-control processes in perception and memory
	Chara Malapani, USA	Presenter
004	The ketamine model of schizophrenia and semantic memory
	Erica Neill, Australia	Presenter
005	Episodic memory in schizophrenic patients, their biological relatives and normal people
	Gholam Ali Nikpour, Iran	Presenter
006	Neural correlates of the recognition processing of emotional words in patients with schizophrenia
	Jae-Jin Kim, Korea, Republic of	Presenter
007	Differential impairment of mesolimbic reward prediction and prediction error processing in unmedicated schizophrenics
	Jan Reuter, Germany	Presenter
008	Perinatal immune activation impairs emotional and cognitive functions with altered hippocampal glutamatergic neurotransmission in adult mice
	Kiyofumi Yamada, Japan	Presenter
009	Improvement in cognitive functioning in schizophrenia after 6-month treatment with olanzapine
	Adam Klasik, Poland	Presenter
010	Impact of cognitive functions and anxiety on the quality of life in schizophrenia
	Krzysztof Krysta, Poland	Presenter
011	Improvement of immediate and delayed recall in schizophrenia after a 6-month rehabilitation program
	Maria Veroniki Karidi, Greece	Presenter
012	Influence of psychopharmacotherapy on the aspects of secual self-perception in patients suffering from schizophrenia or depression
	Djulijano Ljubicic, Croatia	Presenter
013	Efficacy of modafinil in treating clozapine-associated sedation in patients with schizophrenia
	Nikolaos Kouroumalos, Greece	Presenter
015	Cognitive measures in healthy controls and schizophrenic probands
	Sara Pereira, Portugal	Presenter
016	Reducing stigma and discrimination against people with mental disorders
	Snezana Djordjevic, Serbia and Montenegro	Presenter
017	Synergistic impacts of DISC1 mutation and neonatal polyI: C treatment on adult phenotypes in mice: A novel mouse model of schizophrenia with gene - environment interactions
	Taku Nagai, Japan	Presenter
018	Psychopathologic changes after anticholinergic challenge in drug-free patients with schizophrenia and healthy volunteers
	Tanja Veselinovic, Germany	Presenter
019	Relationship between thyroid hormone concentrations and severity of mental symptoms in acute psychoses
	Vesta Steibliene, Lithuania	Presenter

No.	S-89 - Symposium
Time:	14.00-15.30
Room:	Room 252B
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	New insights into abnormal neural oscillations in schizophrenia and the structural and receptor basis of the abnormal neural circuitry
	Robert McCarley, USA	Chair
	Toshiaki Onitsuka, Japan	Co-Chair

001	Gamma band and MRI structural abnormalities in first episode schizophrenia and mania
	Robert McCarley, USA	Speaker
002	Abnormal neural oscillatory activity to speech sounds in schizophrenia: An MEG study
	Toshiaki Onitsuka, Japan	Speaker
003	High-frequency oscillations during perceptual organisation in first-episode and chronic schizophrenia
	Peter Uhlhaas, Germany	Speaker
004	N-methyl-D-aspartic acid receptor antagonist induced frequency oscillations in mice recreates pattern of electrophysiological deficits in schizophrenia
	Steven Siegel, USA	Speaker

« Back

---